Clinical Trials

A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With Cutaneous T-Cell Lymphoma (CTCL)

USA
Texas
Houston

This is a Phase II clinical trial aimed at treating patients with T-cell lymphomas (T-cell blood cancers). The drug consists of a toxin, called diphtheria toxin, which is attached to an antibody that can specifically target cancerous T-cells. Our primary objectives are, therefore, to determine the patient subgroup with respect to disease burden who best responds to this experimental drug in treating CD3 positive T cell malignancies. We will be determining how the patient and their disease respond to this research agent.

For more information: http://clinicaltrials.gov/ct2/show/study/NCT00611208?view=record

Travel & Lodging Defrayment
As a result of study participation, travel will be requested to a participating medical center. Angimmune (the study sponsor) will partially pay to defray travel & lodging costs for a family member to accompany a patient to this trial. Please contact the appropriate Clinical Research Coordinator at the trial site listed below for more information.

University of Texas MD Anderson Cancer Center -    Recruiting
Houston, Texas, United States, 77030
Contact: Carol Wilson, RN    713-563-4655    clwilson@mdanderson.org   
Contact: Vicki Jeanis, RN    713-745-0367    vjeanis@mdanderson.org   
Principal Investigator: Madeleine Duvic, MD         
Sub-Investigator: Susan O'Brien, MD   

Link: http://utm-ext01a.mdacc.tmc.edu/dept/prot/clinicaltrialswp.nsf/Index/2008-0077